Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis

Abstract

After resolution of irEC symptoms, reinitiation of ICI with concurrent SIT is safe, reduces severe irEC recurrence, and has no negative impact on survival outcomes.